DiaSorin Completes the CLIA Panel of Bacterial Gastrointestinal Infections, with the Launch of Campylobacter

DiaSorin (FTSE Mid Cap: DIA) launches the LIAISON Campylobacter test for the market outside the US, completing the bacterial stool-testing panel that includes Clostridium, EHEC, H. pylori. The LIAISON Campylobacter enables laboratories to reduce the time to result and allows patients to know immediately whether they are infected by the bacteria. The LIAISON Campylobacter is the 8th test launched as part of our stool-testing offer and is one of the most frequently occurring bacterial agents of gastroenteritis. The true incidence of gastroenteritis due to Campylobacter is poorly known, particularly in emerging markets; studies in high-income countries have estimated the annual incidence at between 4.4 and 9.3 per 1000 population. In the US an estimated 2 million cases of Campylobacter enteritis occur annually, accounting for 5-7% of cases of gastroenteritis. Today, to diagnose Campylobacter, laboratories use mainly fecal-culture that takes at least 3 days and requires careful handling of the sample, problems that the new Campylobacter will solve. It is important to diagnose Campylobacter in time, considering that 36% of patients with severe Campylobacter infections develop inflammatory chronic bowel syndrome (IBS) within 1–2 years. Until now, Campylobacter has been considered a lower problematic, but the technology developed by DiaSorin will allow laboratories and therefore doctors to answer in due time with an appropriate treatment in the early stage of the disease. Carlo Rosa, CEO of DiaSorin Group, commented: “With the launch of our LIAISON Campylobacter we complete the first and most important part of the Infectious disease stool-testing offer: the bacterial panel. We offer an alternative solution to laboratories that today are using culture, allowing results in less than 1 hour”.